[1] CARTER EE, BSRR SG, CLARKE AE.The global burden of SLE:prevalence, health disparities and socioeconomic impact[J].Nat Rev Rheumatol, 2016, 12(10):605. doi: 10.1038/nrrheum.2016.137
[2] JÖNSEN A, HJALTE F, WILLIM M, et al.Direct and indirect costs for systemic lupus erythematosus in Sweden.A nationwide health-economic study based on five defined cohorts[J].Semin Arthritis Rheum, 2016, 45(6):684. doi: 10.1016/j.semarthrit.2015.11.013
[3] PARK SY, JOO YB, SHIM J, et al.Direct medical costs and their predictors in South Korean patients with systemic lupus erythematosus[J].Rheumatol Int, 2015, 35(11):1809. doi: 10.1007/s00296-015-3344-8
[4] ZHU TY, TAM LS, LI EK.Cost-of-illness studies in systemic lupus erythematosus:a systematic review[J].Arthritis Care Res, 2011, 63:751. doi: 10.1002/acr.20410
[5] CHIU YM, CHUANG MT, LANG HC, et al.Medical costs incurred by organ damage caused by active disease, comorbidities and side effect of treatments in systemic lupus erythematosus patients:a Taiwan nationwide population-based study[J].Rheumatol Int, 2016, 36(11):1507. doi: 10.1007/s00296-016-3551-y
[6] HOCHBERG MC.Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus[J].Arthritis Rheum, 1997, 40(9):1725.
[7] BOMBARDIER C, GLADMAN DD, UROWITZ MB, et al.Derivation of the SLEDAI:a disease activity index for lupus patients.The committee on prognosis studies in SLE[J].Arthritis Rheum, 1992, 35(6):630. doi: 10.1002/art.1780350606
[8] 张乐, 王慧静, 刘喆, 等.上海市系统性红斑狼疮患者的治疗依从性及经济负担状况分析[J].中国现代应用药学, 2018, 35(12):1881.
[9] TANAKA Y, MIZUKAMI A, KOBAYASHI A, et al.Disease severity and economic burden in Japanese patients with systemic lupus erythematosus:a retrospective, observational study[J].Int J Rheum Dis, 2018, 21(8):1609. doi: 10.1111/1756-185X.13363
[10] 李春哲, 潘志侠, 李鹏, 等.医保与非医保患者住院费用的影响因素分析[J].现代生物医学进展, 2016, 16(35):6959.